tbuckley/cabot-search huggingface dataset:
AB0476 Inner ear involvement in systemic rheumatic diseases
Authors: G Tsirves, PV Voulgari, D Archimandriti, E Pelechas, D Asimakopoulos, AA Drosos
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Patients with systemic rheumatic diseases have increased prevalence of sensorineural hearing loss (SNHL). Detection of cochlin specific antibodies has been reported in patients with idiopatic sensorineural hearing loss. Interestingly, cochlin has been shown a stronger link to autoimmune hearing loss. <h3>Objectives</h3> Objective of this cross-sectional study was to calculate the prevalence of SNHL in patients with systemic rheumatic diseases and to detect human cochlin antibodies in their sera. <h3>Methods</h3> This was a prospective study. Patients older that 18 year old who gave informed consent and fulfilled the criteria of American College of Rheumatology for rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren9s syndrome (SS) and systemic sclerosis (SSc) were included. Complete head and neck clinical examination was performed, including otoscopy, nasendoscopy and hearing investigation with pure tone audiometry (250Hz -8000Hz). All medical treatments as well as Disease activity score (DAS) 28 for RA and SLE disease activity index (SLEDAI) for SLE were documented. An average tone loss was calculated, taking as a starting point the loss in dB at various frequencies according the American Committee on Hearing and Equilibrium Guidelines for Meniere9s disease and also recommendation 02/1 of "Bureau International d9 Audiophonologie" (BIAP). Blood samples of the patients were tested for the presence of IgG anti-cochline antibodies (COCH-IgG). The results were compared with those of sex and age-matched healthy subjects. <h3>Results</h3> We studied 133 patients (60 with RA, 41 with SLE, 24 with SS and 8 with SSc) and 133 healthy subjects.61.4% of patients reported vertigo, 41% hyperacousis, 39% hearing loss, 38% tinnitus, 37.9% headache and 2.1% sensation of ear pressure with unremarkable otoscopy. The prevalence of SNL was increased in patients affected by RA, SLE, SS and SSc in comparison to healthy controls (66.6%, 31.71%, 54.17% and 75% respectively). The average hearing thresholds (AHT) calculated using BIAP recommendation 02/1 were significantly increased in RA compared to SLE. AHT were also increased in patients with RA and secondary SS but without statistical significance compared to RA patients. There was a statistically significant correlation between AHT and DAS28 in RA. No correlation observed between AHT and SLEDAI. COCH-IgG were detected in two samples (one patient with RA and one with RA and SS). <h3>Conclusions</h3> Cochlin has been shown to have a stronger link to autoimmune hearing loss, but our study concluded no correlation of hearing loss with human cochlin IgG (COCH). Additional prospective studies are needed to elucidate its pathogenesis. <h3>Disclosure of Interest</h3> None declared
AB1137 The role of social determinants on the prevalence of rheumatic diseases in latin america. a multilevel copcord study
Authors: J Moreno-Montoya, C Pacheco-Tena, Y Granados, J Londoño, S Guevara-Pacheco, B Pons-Estel, O Vega-Hinojosa, M Garza-Elizondo, MV Goycochea-Robles, R Quintana, F Julian-Santiago, J Alvarez-Nemegyei, AM Santos-Granados, R Burgos-Vargas, I Pelaez-Ballestas
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> To determine the impact of individual and regional variables on the geographic distribution of RD across six Latin-American countries <h3>Methods</h3> This is a secondary multilevel analysis of cross-sectional data of COPCORD studies that investigated the prevalence of RD in Argentina, Colombia, Ecuador, México, Peru, and Venezuela. Individual factors were sex, age, comorbidities, job status, and Health Assessment Questionnaire (HAQ) score. Contextual level variables were country and subject9s identification as indigenous. RD predictors, including individual and regional variables, particularly indigenous status were identified with logistic regression models. The effect of contextual variables was estimated with median odds ratio9s (OR) estimation. <h3>Results</h3> Most individuals included in this analysis came from urban areas (82.40%); their mean age was 43.12 years (95% CI 43.01–43.35); and 56.0% were women. Nearly all of them reported &gt;1 comorbidity (94.70%) and 72.19% were economically active. The prevalence of any RD varied from 1.55% in Peru to 26.09% in Argentina. The mean prevalence of Rheumatoid Arthritis (RA) was 1.58 (range 0.64 to 2.47) (table 1). Aside comorbidities, individual level variables associated to any RD were sex (OR: 1.35; 95% CI 1.28–1.43), age (OR: 1.02; 95% CI 1.01 -1.03), and HAQ score (OR: 3.71; 95% CI 3.22–4.28). Crude comparisons showed significant variations among countries (p&lt;0.01) and indigenous groups (OR: 1.69; 95% CI 1.58–1.81). These findings were confirmed by adjusted analysis (Median OR 1.26; 95% CI 1.14–1.38) (table 2). <h3>Conclusions</h3> There common factors associated to the prevalence of RD in the region, however, the estimation of its impact varies in significant way across countries and related to the fact of belong to an indigenous group indicating an increase in the estimated ORs. <h3>Acknowledgements</h3> National Council for Science and Technology (CONACYT);Colegio Mexicano de Reumatologia (Mexico). EsSalud (Perú). Universidad de Cuenca (Ecuador).ASOREUMA (Colombia). Federico Wilhelm Agricola Foundation (Argentina). PDVSA East, SUELOPETROL and Bristol-Myers Laboratory (Venezuela) <h3>Disclosure of Interest</h3> None declared
Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.
Authors: Clasina Marieke Venema, Lemonitsa H. Mammatas, Michel van Kruchten, Giulia Apollonio, Carolina Pia Schroder, Andor W. J. M. Glaudemans, Otto S. Hoekstra, Henk M.W. Verheul, Bert van der Vegt, Erik F. J. De Vries, Elisabeth De Vries, Catharina Wilhelmina Menke, Geke Hospers
Journal: Journal of Clinical Oncology (2016)

11553 Background: The ER, PR and HER2 expression is routinely determined in breast cancer patients for prognosis and treatment decision-making. The androgen receptor (AR) is also present in the majority of breast cancer patients, offering a potential new drug target.ER expression in tumor lesions can be visualized by 18F-fluoroestradiol (FES) PET throughout the body. The AR-expression could be visualized by 18F-fluorodihydrotestosterone (FDHT) PET in prostate cancer patients.The aim was to obtain accurate non-invasive information about ER and AR tumor receptor status with FES and FDHT PET in breast cancer patients. Methods: Metastatic breast cancer patients with an ER positive primary tumor and ≥ 1 metastasis were eligible. Patients were staged with a bone scan and chest and abdominal CT scan. Lesions visible on conventional imaging were evaluable for primary endpoint, i.e. the concordance of FES and FDHT uptake with respectively ER and AR expression determined immunohistochemically (IHC) in a metastasis. Patients underwent a FES PET and FDHT PET scan within 2 weeks. ER and AR staining was performed centrally according to ASCO guidelines. IHC > 10% and > 1% nuclear staining was considered AR and ER positive, respectively. Correlations between PET and IHC were calculated using Spearman’s correlation coefficient. Results: 13/24 patients were evaluable for the primary endpoint. 5 patients had non-representative biopsies, biopsied liver lesions (n = 3) were not evaluable on PET due to high physiological background uptake in healthy tissue. 2 skin lesions and 1 intestinal lesion were not visible on conventional imaging. The correlation between AR expression and FDHT uptake (SUVmax ) was ρ: 0.67 (p = 0.01) and between ER expression and FES uptake was ρ: 0.75(p = 0.003). Conclusions: It is feasible to visualize AR expressing lesions with FDHT PET in metastatic breast cancer patients, and FDHT uptake correlates with AR expression in representative biopsies. FES uptake shows a similar correlation with ER expression. Supported by CTMM-Mammoth project. Clinical trial information: NCT01988324.Mean uptake (SUVmax) of biopsied lesions per subgroup. PET/IHC AR > 10% n = 11 AR < 10% n = 2 ER > 1% n = 11 ER < 1% n = 2 FDHT (SD) 3.05 (0.90) 1.89 (0.01) FES (SD) 4.30 (2.42) 1.13 (0.42)
SAT0657 Can vascular inflammation in ra be detected using contrast enhanced mri? preliminary results
Authors: S Skeoch, R Little, Y Watson, S Cheung, J O'Connor, Y Alexander, I Bruce, G Parker, J Waterton
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> In rheumatoid arthritis (RA) vascular inflammation may contribute to excess cardiovascular (CV) risk. Contrast enhanced MRI has been used to detect vascular inflammation in Takayasu9s arteritis. In RA, its utility has not been studied but it may provide a method of identifying and monitoring vascular inflammation and effects of therapy. <h3>Objectives</h3> We sought to compare carotid artery wall enhancement on contrast enhanced MRI in RA patients and controls and evaluate association with circulating markers of inflammation, endothelial activation and CV risk factors. <h3>Methods</h3> Patients and age/sex matched controls underwent clinical and serological assessment (details in Table 1) and a screening carotid ultrasound. Those with wall thickening&gt;2mm had a carotid MRI. T<sub>1</sub>-weighted images were acquired before and after gadopentate injection on a 3T scanner. Increase in mean signal intensity (SI) in the carotid vessel wall normalised to adjacent skeletal muscle provided a global enhancement metric (WE<sub>G</sub>). Histograms of distribution of SIs on pre-and post- contrast images were generated and bimodal Gaussian distributions fitted to explore patterns of enhancement within the wall. MRI measurements were compared between groups and association with serological markers tested using non-parametric statistics. <h3>Results</h3> 27 patients and 10 controls underwent MR imaging. Key characteristics are seen in Table 1. There was no difference in WE<sub>G</sub> between groups and no association with serological markers. However a bimodal distribution of SI in vessel wall was observed (Figure 1) and in exploratory analysis these two components were analysed separately. For the low-signal component enhancement (WE<sub>low</sub>) correlated with ESR, I-CAM, e-selectin (r=0.39,p=0.03;r=0.44,p=0.01;r=0.37,p=0.04). There was a trend towards correlation with CRP (r=0.30,0.08) and towards higher values in patients (median 0.20 (0.15, 0.33) vs 0.14 (0.11, 0.22),p=0.051). Enhancement in the high-signal component (WE<sub>high</sub>) was not associated with serological markers or RA status. <h3>Conclusions</h3> Simple global SI measurement on MRI did not suggest vascular inflammation in RA. However, the bimodal SI distribution may represent different wall components e.g. intima and adventitia. The differential enhancement, and association of WE<sub>low</sub> with inflammation, endothelial activation and RA status, warrants further investigation. <h3>Disclosure of Interest</h3> None declared
How well does the psychiatry residency in-training examination predict performance on the American Board of Psychiatry and Neurology. Part I. Examination?
Authors: Lynn C. Webb, Dorthea Juul, Charles F. Reynolds, Beth Ruiz, Pedro Ruiz, Stephen C. Scheiber, James Scully
Journal: American Journal of Psychiatry (1996)

Scores on the American College of Psychiatrists' Psychiatry Residency In-Training Examination (PRITE) were correlated with scores on the American Board of Psychiatry and Neurology (ABPN) Part I examination in psychiatry.Pearson correlations between 1992 PRITE scores and 1994 ABPN Part I psychiatry scores were calculated. Analyses were based on 701 examinees.There was a moderate correlation between scores on the PRITE and ABPN Part I examination in psychiatry and a low correlation of neurology scores.These correlations were observed even though the two examinations differ in their purposes, content outlines, development, and administration.
THU0507 Long-term experience with adalimumab for the treatment of juvenile idiopathic arthritis. 5- year data from the german biker registry
Authors: A Klein, K Minden, I Foeldvari, G Ganser, JP Haas, R Trauzeddel, A Hospach, F Weller-Heinemann, G Horneff
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Since the approval of Adalimumab (ADA) for treatment of juvenile idiopathic arthritis (JIA), it has become a valuable option, which significantly improved the outcome of patients. <h3>Objectives</h3> To report efficacy (as observed) and safety of ADA in clinical practice. <h3>Methods</h3> Data from the German BiKeR register from 2011 to 2016 are reported. Baseline patient characteristics, treatment response and safety data were compared. Treatment response was analyzed using JIA-ACR criteria, JADAS score and improvement of functional status (Childhood Health Assessment Questionnaire disability index, CHAQ), JIA-ACR-scores, JADAS10-minimal disease activity (MDA), JADAS-remission and ACR-inactive disease criteria were analysed. <h3>Results</h3> 589 non-systemic JIA patients exposed to Adalimumab with at least one follow-up report were identified in the German BIKER registry, representing 1143.9 patient years (PY) of exposure to ADA and 1206.5 observation years including 90 days after discontinuation. At Baseline, 58.2% received combination with methotrexate (MTX). Patients on combination treatment had more frequently ANA, less frequently HLA-B27, had higher JADAS 10 and more often received systemic steroids (9.9% vs. 22.2%, p=0.0002). ADA dosage was 0.8mg/kg in both cohorts. At month 12 JIA-ACR 30/50/70/90 and JADAS-MDA/-remission/ACR-inactive disease was reached by 66/63/49/33/50/24/27% on monotherapy with ADA and 68/63/45/28%/50/28/27 on combination of ADA and MTX (not significant). Response rates at month 24 were 67/66/54/35/65/32/29% on ADA monotherapy and 67/61/46/31/57/35/30% on ADA+MTX combination cohort (not significant). The rate (/100PY) of all adverse events (AE)/serious AE/infections/serious infections/uveitis events was 52.3/2.2/16.4/4.6 upon monotherapy and 65.3/5.1/2.3/16.4/6.2 upon combination. Only rates for any AE were significantly higher upon combination (p=0.008) as well as rate of elevated transaminase (p=0.01). Rate of patients with an uveitis event was higher upon combination (9.6% vs. 5.3%, p=0.007) <h3>Conclusions</h3> Adalimumab demonstrated high response rates and an acceptable risk profile. Efficacy and safety of monotherapy was not inferior to combination therapy with MTX. <h3>Disclosure of Interest</h3> A. Klein: None declared, K. Minden Speakers bureau: Abbvie, Pfizer,Roche,Genzyme,Pharm-Allergan, I. Foeldvari: None declared, G. Ganser: None declared, J. Haas: None declared, R. Trauzeddel: None declared, A. Hospach: None declared, F. Weller-Heinemann: None declared, G. Horneff Grant/research support from: Abbvie, Chugai, Novartis, Pfizer,Roche
Unemployment in chronic airflow obstruction around the world: results from the BOLD study
Authors: Rune Grønseth, Marta Erdal, Wan C. Tan, Daniel O. Obaseki, Andre F.S. Amaral, Thorarinn Gislason, Sanjay K. Juvekar, Parvaiz A. Koul, Michael Studnicka, Sundeep Salvi, Peter Burney, A. Sonia Buist, William M. Vollmer, Ane Johannessen
Journal: European Respiratory Journal (2017)

We aimed to examine associations between chronic airflow obstruction (CAO) and unemployment across the world. Cross-sectional data from 26 sites in the Burden of Obstructive Lung Disease (BOLD) study were used to analyse effects of CAO on unemployment. Odds ratios for unemployment in subjects aged 40–65 years were estimated using a multilevel mixed-effects generalised linear model with study site as random effect. Site-by-site heterogeneity was assessed using individual participant data meta-analyses. Out of 18 710 participants, 11.3% had CAO. The ratio of unemployed subjects with CAO divided by subjects without CAO showed large site discrepancies, although these were no longer significant after adjusting for age, sex, smoking and education. The site-adjusted odds ratio (95% CI) for unemployment was 1.79 (1.41–2.27) for CAO cases, decreasing to 1.43 (1.14–1.79) after adjusting for sociodemographic factors, comorbidities and forced vital capacity. Of other covariates that were associated with unemployment, age and education were important risk factors in high-income sites (4.02 (3.53–4.57) and 3.86 (2.80–5.30), respectively), while female sex was important in low- to middle-income sites (3.23 (2.66–3.91)). In the global BOLD study, CAO was associated with increased levels of unemployment, even after adjusting for sociodemographic factors, comorbidities and lung function.
AB1028 Prevalence and distribution of sesamoid bones in the hand determined using digital tomosynthesis
Authors: HH Kwon, BS Koo, Y Song, Y-K Sung, S Lee, J-B Jun
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Sesamoid bones are round or oval-shaped bones that are embedded in tendons. The prevalence and distribution of sesamoids in the hand varies between different populations. Conventional radiography (CR) is generally used to identify the sesamoid bones. However, there was no study using digital tomosynthesis (DTS). <h3>Objectives</h3> The aim of this study was to identify the prevalence and distribution of sesamoid bones in the hand using DTS in comparison to previous studies. <h3>Methods</h3> Using CR and DTS, hand images (81 left and 100 right) taken at a tertiary hospital were retrospectively reviewed. The sesamoid bones were identified in the distal interphalangeal (DIP), interphalangeal (IP), and metacarpophalangeal (MCP) of the thumb (I), index (II), long (III), ring (IV), and small (V) fingers. Differences in number of sesamoid bones detected on CR and DTS were analyzed. <h3>Results</h3> Sesamoid bones were observed in MCP I (100%), MCP II (46%), MCP III (2%), MCP IV (2%), MCP V (53%), and IP (53%) on CR. Using DTS, sesamoid bones were found more often in MCP I (100%), MCP II (54%), MCP III (2%), MCP IV (1%), MCP V (59%), and IP (75%). Differences in the mean number of sesamoid bones detected on CR and DTS were statistically significant. Sesamoid bones in DIP joints were frequently observed on DTS, but rarely found on CR. <h3>Conclusions</h3> Most sesamoid bones in the hand were detected in MCP I, II, V, and IP joints, and were more often detected on DTS than CR. DTS is a reliable tool to evaluate bony structures in the hand. <h3>Disclosure of Interest</h3> None declared
AB0430 Leflunomide as a second line dmard after methotrexate has limited impact on rheumatoid arthritis in real life
Authors: G Weigt, A Erler, M Aringer
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> If rheumatoid arthritis (RA) is not in remission or at least low disease under methotrexate (MTX), leflunomide is an approved conventional synthetic DMARD, which is commonly used in some countries. <h3>Objectives</h3> To investigate in a real life situation whether patients with RA benefit from instituting leflunomide after methotrexate. <h3>Methods</h3> The clinical data of all RA patients who had at least once received leflunomide, and who agreed to the pseudonymized analysis of their data (approved by the local ethics committee), were analyzed from the time of leflunomide initiation on to the time of stopping leflunomide or the last visit in 2015, which ever came first. <h3>Results</h3> In total, 145 RA patients treated with leflunomide were identified. Of these, 87 received leflunomide after MTX had failed as a first line DMARD, and 8 received leflunomide as a first line DMARD. 50 patients had another first line therapy. Of the first line leflunomide patients 3 (38%) were still on leflunomide at the last visit, as compared to 7 of the 44 patients (16%) who were switched from MTX to leflunomide, and 0 of the 27 patients in whom leflunomide was added to MTX (p&lt;0.01 vs 1st line leflunomide). For leflunomide monotherapy, 29% and 19% were still on the drug after 24 and 48 months, respectively, as compared to 14 and 0% under the combination with MTX. Of all patients who started leflunomide, remission (at least low disease activity) as per CDAI (≤2.8 (≤10)) was reached by 23% (57%) 3 months, 20% (40%) 6 months, and 16% (34%) one year after initiating leflunomide monotherapy, with corresponding percentages of patients of 39% switched to other approaches at six months and of 60% switched at one year. Under the combination of leflunomide and MTX, remission (at least low disease activity) was seen in 18% (53%) at 3 months, 20% (37%) at 6 months, and 8% (20%) at one year, and 55% and 71% had switched to other modes of action at six months and one year, respectively. Gastrointestinal and mucocutaneous adverse events and hypertension were common, and 4 our patients experienced serious bacterial infections. <h3>Conclusions</h3> Leflunomide constitutes a longer term option for a subgroup of RA patients with contraindications to MTX or after MTX failure. After one year, leflunomide had led to sustained acceptable disease control in approximately one third of the patients, but only in one in five under leflunomide combined with MTX. These results are supportive of the EULAR recommendations that patients should be switched to a second conventional DMARD in the absence of predictors of bad outcome only. If leflunomide is initiated, the patients need to be followed closely for potential secondary loss of efficacy. <h3>Disclosure of Interest</h3> None declared
Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency
Authors: Hassan Abolhassani, Janet Chou, Wayne Bainter, Craig D. Platt, Mahmood Tavassoli, Tooba Momen, Marzieh Tavakol, Mohammad Hossein Eslamian, Mohammad Gharagozlou, Masoud Movahedi, Mohsen Ghadami, Amir Ali Hamidieh, Gholamreza Azizi, Reza Yazdani, Mohsen Afarideh, Alireza Ghajar, Arash Havaei, Zahra Chavoshzadeh, Seyed Alireza Mahdaviani, Taher Cheraghi, Nasrin Behniafard, Reza Amin, Soheila Aleyasin, Reza Faridhosseini, Farahzad Jabbari-Azad, Mohammamd Nabavi, Mohammad Hassan Bemanian, Saba Arshi, Rasol Molatefi, Roya Sherkat, Mahboubeh Mansouri, Mehrnaz Mesdaghi, Delara Babaie, Iraj Mohammadzadeh, Javad Ghaffari, Alireza Shafiei, Najmeddin Kalantari, Hamid Ahanchian, Maryam Khoshkhui, Habib Soheili, Abbas Dabbaghzadeh, Afshin Shirkani, Rasoul Nasiri Kalmarzi, Seyed Hamidreza Mortazavi, Javad Tafaroji, Abbas Khalili, Javad Mohammadi, Babak Negahdari, Mohammad-Taghi Joghataei, Basel K. al-Ramadi, Capucine Picard, Nima Parvaneh, Nima Rezaei, Talal A. Chatila, Michel J. Massaad, Sevgi Keles, Lennart Hammarström, Raif S. Geha, Asghar Aghamohammadi
Journal: Journal of Allergy and Clinical Immunology (2017)